TERT promoter mutation sydding with adverse prognosis of invasive meningioma

Ref: Spiegl-Kreinecker S , et alNeuro Oncol2018 Nov 12;20 (12):1584-1593doi: 10.1093/neuonc/noy104meningioma is a common intracranial benign tumor, but has a tendency to malignantly changeIt has been studied that mutations in the gene promoter region of telomerase (telomerase reverse transcriptase, TERT) are relatively rare in meningioma, but they can be used to predict the risk of tumor progression and recurrenceSabine Spiegl-Kreinecker of Kepler University Hospital, University of Johannes Kepler, Austria, and others explained the effects of TERT promoter mutations on patients' prognosis and in vitro proliferation of tumor cells through the study of WHO I-III-grade meningioma patientsThe results were published in The Neuro-Oncology in November 2018the study included 110 patients with meningioma, including 128 samples of meningiomaThe in vitro proliferation capacity of 121 meningioma cells was directly sequenced and evaluated at the TET promoter mutation sites C228T and C250TOne by one, experimental methods such as telomere repeated amplification program (TRAP), RT-PCR and qPCR were implemented to determine telomerase activity, TERT mRNA expression levels and telomere length in meninge tumor specimensSequencing results showed that 5.5% of the meningioma specimentertt sons had mutations and were significantly associated with telomerase activity and a significant increase in TERT mRNA expression (P 0.0001)no difference in telomere length was detected in the wild and mutant meningiomas of TERT promotersThe total survival of PATIENTS WITH TERT promoter mutant meningioma was significantly reduced (53.8 months compared to 115.6 months; P-0.0006)The ability of transmen's in vitro proliferation of TERT promoter mutations in meningioma cells does not depend on the activity of telomerase and telomere lengthIn the process of screening anti-tumor-sensitive drugs, the researchers found that the meningioma cells of terT promoter mutations were highly sensitive to the ETS transcription factor inhibitor YK-4-279, which induces the loss of activity of the mutant TERT promoter to inhibit tumor cell proliferationauthors concluded that TERT promoter mutations are one of the main factors contributing to the aggressiveness of meningioma, resulting in a significant reduction in patient survival Targeted treatment storts for TERT promoter mutations may be a new way to treat invasive meningiomas.